Arrowhead Pharmaceuticals (NASDAQ: ARWR) stock is soaring 5.02% in Tuesday's trading session, driven by a significant milestone payment and anticipation of its upcoming earnings report. The biotechnology company's shares are gaining momentum following news of a $200 million payment from Sarepta Therapeutics and the scheduled release of its fourth-quarter financial results.

The substantial payment from Sarepta Therapeutics was triggered by progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003, an investigational small-interfering RNA (siRNA) therapeutic for type 1 myotonic dystrophy (DM1). This development highlights the value of Arrowhead's technology and partnerships in the pharmaceutical industry, boosting investor confidence in the company's potential for future revenue streams.

Adding to the positive sentiment, Arrowhead Pharmaceuticals is set to report its fourth-quarter earnings after the market closes on Tuesday. Analysts expect the company to report earnings per share of ($0.11) for the quarter. The combination of the milestone payment and the imminent financial results is likely contributing to the stock's upward movement as investors position themselves ahead of the earnings announcement. Additionally, B. Riley Securities has reiterated a Buy rating on Arrowhead Pharmaceuticals with a price target of $61.00, further supporting the bullish outlook on the stock.